Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 51

1.

Inflammatory markers in cerebrospinal fluid: independent prognostic biomarkers in amyotrophic lateral sclerosis?

Gille B, De Schaepdryver M, Dedeene L, Goossens J, Claeys KG, Van Den Bosch L, Tournoy J, Van Damme P, Poesen K.

J Neurol Neurosurg Psychiatry. 2019 Jun 7. pii: jnnp-2018-319586. doi: 10.1136/jnnp-2018-319586. [Epub ahead of print]

PMID:
31175169
2.

Antinuclear antibodies by indirect immunofluorescence and solid phase assays.

Bossuyt X, Claessens J, De Langhe E, Belmondo T, Westhovens R, Hue S, Poesen K, Blockmans D, Mahler M, Fritzler MJ.

Ann Rheum Dis. 2019 May 10. pii: annrheumdis-2019-215443. doi: 10.1136/annrheumdis-2019-215443. [Epub ahead of print] No abstract available.

PMID:
31076390
3.

An ALS case with 38 (G4C2)-repeats in the C9orf72 gene shows TDP-43 and sparse dipeptide repeat protein pathology.

Dedeene L, Van Schoor E, Race V, Moisse M, Vandenberghe R, Poesen K, Van Damme P, Thal DR.

Acta Neuropathol. 2019 May;137(5):855-858. doi: 10.1007/s00401-019-01996-z. Epub 2019 Mar 27. No abstract available.

PMID:
30919029
4.

Clinical spectrum of the anti-GQ1b antibody syndrome: a case series of eight patients.

de Bruyn A, Poesen K, Bossuyt X, Heremans IP, Claeys T, Depuydt CE, Van Damme P, Claeys KG.

Acta Neurol Belg. 2019 Mar;119(1):29-36. doi: 10.1007/s13760-019-01093-8. Epub 2019 Feb 12.

PMID:
30747336
5.

Cerebrospinal fluid levels of synaptic and neuronal integrity correlate with gray matter volume and amyloid load in the precuneus of cognitively intact older adults.

Schaeverbeke J, Gille B, Adamczuk K, Vanderstichele H, Chassaing E, Bruffaerts R, Neyens V, Stoops E, Tournoy J, Vandenberghe R, Poesen K.

J Neurochem. 2019 Apr;149(1):139-157. doi: 10.1111/jnc.14680. Epub 2019 Mar 20.

PMID:
30720873
6.

Diagnostic and Prognostic Performance of Neurofilaments in ALS.

Poesen K, Van Damme P.

Front Neurol. 2019 Jan 18;9:1167. doi: 10.3389/fneur.2018.01167. eCollection 2018. Review.

7.

Analytical performance of a CE-marked immunoassay to quantify phosphorylated neurofilament heavy chains.

De Schaepdryver M, Goossens J, Jeromin A, Brix B, Van Damme P, Poesen K.

Clin Chem Lab Med. 2019 Feb 2. pii: /j/cclm.ahead-of-print/cclm-2018-1004/cclm-2018-1004.xml. doi: 10.1515/cclm-2018-1004. [Epub ahead of print] No abstract available.

PMID:
30710472
8.

The Chromosomal Conformation Signature: A New Kid on the Block in ALS Biomarker Research?

Poesen K.

EBioMedicine. 2018 Jul;33:6-7. doi: 10.1016/j.ebiom.2018.07.003. Epub 2018 Jul 7. No abstract available.

9.

The effect of xenon-augmented sevoflurane anesthesia on intraoperative hemodynamics and early postoperative neurocognitive function in children undergoing cardiac catheterization: A randomized controlled pilot trial.

Devroe S, Lemiere J, Van Hese L, Gewillig M, Boshoff D, Poesen K, Van de Velde M, Rex S.

Paediatr Anaesth. 2018 Aug;28(8):726-738. doi: 10.1111/pan.13444. Epub 2018 Jul 13.

PMID:
30004615
10.

Serum neurofilament light chain levels as a marker of upper motor neuron degeneration in patients with Amyotrophic Lateral Sclerosis.

Gille B, De Schaepdryver M, Goossens J, Dedeene L, De Vocht J, Oldoni E, Goris A, Van Den Bosch L, Depreitere B, Claeys KG, Tournoy J, Van Damme P, Poesen K.

Neuropathol Appl Neurobiol. 2019 Apr;45(3):291-304. doi: 10.1111/nan.12511. Epub 2018 Jul 18.

PMID:
29908069
11.

Antigen excess detection by automated assays for free light chains.

Bossuyt X, Delforge M, Reynders M, Dillaerts D, Sprangers B, Fostier K, Poesen K, Vercammen M.

Clin Chem Lab Med. 2018 Aug 28;56(9):e235-e238. doi: 10.1515/cclm-2017-0977. No abstract available.

PMID:
29679525
12.

Diagnostic thresholds for free light chains in multiple myeloma depend on the assay used.

Bossuyt X, Delforge M, Reynders M, Dillaerts D, Sprangers B, Fostier K, Poesen K, Vercammen M.

Leukemia. 2018 Aug;32(8):1815-1818. doi: 10.1038/s41375-018-0041-0. Epub 2018 Apr 20. No abstract available.

PMID:
29674643
13.

Solid phase assays versus automated indirect immunofluorescence for detection of antinuclear antibodies.

Claessens J, Belmondo T, De Langhe E, Westhovens R, Poesen K, Hüe S, Blockmans D, Mahler M, Fritzler MJ, Bossuyt X.

Autoimmun Rev. 2018 Jun;17(6):533-540. doi: 10.1016/j.autrev.2018.03.002. Epub 2018 Mar 8. Review.

PMID:
29526634
14.

Detection of myositis-specific antibodies.

Vulsteke JB, De Langhe E, Claeys KG, Dillaerts D, Poesen K, Lenaerts J, Westhovens R, Van Damme P, Blockmans D, De Haes P, Bossuyt X.

Ann Rheum Dis. 2019 Jan;78(1):e7. doi: 10.1136/annrheumdis-2017-212915. Epub 2018 Jan 25. No abstract available.

PMID:
29371203
15.

Automation on an Open-Access Platform of Alzheimer's Disease Biomarker Immunoassays.

Gille B, Dedeene L, Stoops E, Demeyer L, Francois C, Lefever S, De Schaepdryver M, Brix B, Vandenberghe R, Tournoy J, Vanderstichele H, Poesen K.

SLAS Technol. 2018 Apr;23(2):188-197. doi: 10.1177/2472630317750378. Epub 2018 Jan 18.

PMID:
29346009
16.

Screening for connective tissue disease-associated antibodies by automated immunoassay.

Willems P, De Langhe E, Claessens J, Westhovens R, Van Hoeyveld E, Poesen K, Vanderschueren S, Blockmans D, Bossuyt X.

Clin Chem Lab Med. 2018 May 24;56(6):909-918. doi: 10.1515/cclm-2017-0905.

PMID:
29306915
17.

Multicenter evaluation of neurofilaments in early symptom onset amyotrophic lateral sclerosis.

Feneberg E, Oeckl P, Steinacker P, Verde F, Barro C, Van Damme P, Gray E, Grosskreutz J, Jardel C, Kuhle J, Koerner S, Lamari F, Amador MDM, Mayer B, Morelli C, Muckova P, Petri S, Poesen K, Raaphorst J, Salachas F, Silani V, Stubendorff B, Turner MR, Verbeek MM, Weishaupt JH, Weydt P, Ludolph AC, Otto M.

Neurology. 2018 Jan 2;90(1):e22-e30. doi: 10.1212/WNL.0000000000004761. Epub 2017 Dec 6.

PMID:
29212830
18.

Elevated ALS Biomarker Levels in CSF of a FTD Patient at the Presymptomatic Stage of ALS.

Cognat E, De Schaepdryver M, Hugon J, Poesen K, Paquet C.

Alzheimer Dis Assoc Disord. 2018 Apr-Jun;32(2):156-157. doi: 10.1097/WAD.0000000000000222. No abstract available.

PMID:
29189300
19.

Diagnostic thresholds for free light chains in multiple myeloma depend on the assay used.

Bossuyt X, Delforge M, Reynders M, Dillaerts D, Sprangers B, Fostier K, Poesen K, Vercammen M.

Leukemia. 2017 Nov 20. doi: 10.1038/leu.2017.335. [Epub ahead of print]

PMID:
29151583
20.

Comparison of elevated phosphorylated neurofilament heavy chains in serum and cerebrospinal fluid of patients with amyotrophic lateral sclerosis.

De Schaepdryver M, Jeromin A, Gille B, Claeys KG, Herbst V, Brix B, Van Damme P, Poesen K.

J Neurol Neurosurg Psychiatry. 2018 Apr;89(4):367-373. doi: 10.1136/jnnp-2017-316605. Epub 2017 Oct 20.

PMID:
29054919
21.

Xenon as an adjuvant to sevoflurane anesthesia in children younger than 4 years of age, undergoing interventional or diagnostic cardiac catheterization: A randomized controlled clinical trial.

Devroe S, Meeusen R, Gewillig M, Cools B, Poesen K, Sanders R, Rex S.

Paediatr Anaesth. 2017 Dec;27(12):1210-1219. doi: 10.1111/pan.13230. Epub 2017 Sep 5.

PMID:
28872734
22.

Neurofilament markers for ALS correlate with extent of upper and lower motor neuron disease.

Poesen K, De Schaepdryver M, Stubendorff B, Gille B, Muckova P, Wendler S, Prell T, Ringer TM, Rhode H, Stevens O, Claeys KG, Couwelier G, D'Hondt A, Lamaire N, Tilkin P, Van Reijen D, Gourmaud S, Fedtke N, Heiling B, Rumpel M, Rödiger A, Gunkel A, Witte OW, Paquet C, Vandenberghe R, Grosskreutz J, Van Damme P.

Neurology. 2017 Jun 13;88(24):2302-2309. doi: 10.1212/WNL.0000000000004029. Epub 2017 May 12.

PMID:
28500227
23.

Finger extension weakness and downbeat nystagmus motor neuron disease syndrome: A novel motor neuron disorder?

Delva A, Thakore N, Pioro EP, Poesen K, Saunders-Pullman R, Meijer IA, Rucker JC, Kissel JT, Van Damme P.

Muscle Nerve. 2017 Dec;56(6):1164-1168. doi: 10.1002/mus.25669. Epub 2017 May 15.

24.

Tubulointerstitial expression and urinary excretion of connective tissue growth factor 3 months after renal transplantation predict interstitial fibrosis and tubular atrophy at 5 years in a retrospective cohort analysis.

Vanhove T, Kinashi H, Nguyen TQ, Metalidis C, Poesen K, Naesens M, Lerut E, Goldschmeding R, Kuypers DRJ.

Transpl Int. 2017 Jul;30(7):695-705. doi: 10.1111/tri.12960. Epub 2017 May 9.

25.

Negative commercial screening test for paraneoplastic antibodies in a case of opsoclonus.

Vandenbussche N, Cassiman C, Schrooten M, Gille B, Bossuyt X, Vincent T, Van Damme P, Poesen K.

Neurol Neuroimmunol Neuroinflamm. 2017 Feb 3;4(2):e329. doi: 10.1212/NXI.0000000000000329. eCollection 2017 Mar. No abstract available.

26.

Diagnostic Challenges and Clinical Characteristics of Hepatitis E Virus-Associated Guillain-Barré Syndrome.

Stevens O, Claeys KG, Poesen K, Saegeman V, Van Damme P.

JAMA Neurol. 2017 Jan 1;74(1):26-33. doi: 10.1001/jamaneurol.2016.3541.

PMID:
27820624
27.

Three Patients with an Unusual Pattern on Urine Immunofixation.

Schiemsky T, Wils J, Hoet K, Poesen K.

Clin Chem. 2016 Oct;62(10):1412-3. doi: 10.1373/clinchem.2015.253724. No abstract available.

28.

Evaluation of the V8 E-Class, a Novel Automated Capillary Isoelectric Focusing Instrument for Hemoglobinopathy Screening.

Schiemsky T, Brusselmans C, Nackers E, Vermeersch P, Poesen K, Desmet KJ, Boeckx N, Kieffer DM.

Am J Clin Pathol. 2016 Sep;146(3):361-8. doi: 10.1093/ajcp/aqw124.

PMID:
27543981
29.

Homozygous N-terminal missense mutation in TRNT1 leads to progressive B-cell immunodeficiency in adulthood.

Frans G, Moens L, Schaballie H, Wuyts G, Liston A, Poesen K, Janssens A, Rice GI, Crow YJ, Meyts I, Bossuyt X.

J Allergy Clin Immunol. 2017 Jan;139(1):360-363.e6. doi: 10.1016/j.jaci.2016.06.050. Epub 2016 Aug 13. No abstract available.

PMID:
27531075
30.

Multicenter validation of CSF neurofilaments as diagnostic biomarkers for ALS.

Oeckl P, Jardel C, Salachas F, Lamari F, Andersen PM, Bowser R, de Carvalho M, Costa J, van Damme P, Gray E, Grosskreutz J, Hernández-Barral M, Herukka SK, Huss A, Jeromin A, Kirby J, Kuzma-Kozakiewicz M, Amador Mdel M, Mora JS, Morelli C, Muckova P, Petri S, Poesen K, Rhode H, Rikardsson AK, Robberecht W, Rodríguez Mahillo AI, Shaw P, Silani V, Steinacker P, Turner MR, Tüzün E, Yetimler B, Ludolph AC, Otto M.

Amyotroph Lateral Scler Frontotemporal Degener. 2016 Jul-Aug;17(5-6):404-13. doi: 10.3109/21678421.2016.1167913. Epub 2016 Apr 11.

PMID:
27415180
31.

Two Cases of Heavy Chain MGUS.

Van Keer J, Meijers B, Delforge M, Verhoef G, Poesen K.

Case Rep Oncol Med. 2016;2016:8749153. doi: 10.1155/2016/8749153. Epub 2016 Apr 26.

32.

Serum protein S100 as marker of postoperative delirium after off-pump coronary artery bypass surgery: secondary analysis of two prospective randomized controlled trials.

Al Tmimi L, Van de Velde M, Meyns B, Meuris B, Sergeant P, Milisen K, Pottel H, Poesen K, Rex S.

Clin Chem Lab Med. 2016 Oct 1;54(10):1671-80. doi: 10.1515/cclm-2015-1012.

PMID:
26943607
33.

Diagnostic value of cerebrospinal fluid Aβ ratios in preclinical Alzheimer's disease.

Adamczuk K, Schaeverbeke J, Vanderstichele HM, Lilja J, Nelissen N, Van Laere K, Dupont P, Hilven K, Poesen K, Vandenberghe R.

Alzheimers Res Ther. 2015 Dec 18;7(1):75. doi: 10.1186/s13195-015-0159-5.

34.

Xenon for the prevention of postoperative delirium in cardiac surgery: study protocol for a randomized controlled clinical trial.

Al Tmimi L, Van de Velde M, Herijgers P, Meyns B, Meyfroidt G, Milisen K, Fieuws S, Coburn M, Poesen K, Rex S.

Trials. 2015 Oct 9;16:449. doi: 10.1186/s13063-015-0987-4.

35.

Xenon anaesthesia for patients undergoing off-pump coronary artery bypass graft surgery: a prospective randomized controlled pilot trial.

Al Tmimi L, Van Hemelrijck J, Van de Velde M, Sergeant P, Meyns B, Missant C, Jochmans I, Poesen K, Coburn M, Rex S.

Br J Anaesth. 2015 Oct;115(4):550-9. doi: 10.1093/bja/aev303.

36.

Epidemiology of infective endocarditis in a large Belgian non-referral hospital.

Poesen K, Pottel H, Colaert J, De Niel C.

Acta Clin Belg. 2014 Jun;69(3):183-90. doi: 10.1179/0001551214Z.00000000046. Epub 2014 Apr 25.

PMID:
24761948
37.

Historical response factor-based quantification for LC-MS/MS.

Pauwels S, Poesen K, Van Eldere J, Desmet K, Vermeersch P.

Clin Chem. 2013 Nov;59(11):1674-6. doi: 10.1373/clinchem.2013.212761. Epub 2013 Aug 28. No abstract available.

38.

Ecstasy intoxication as an unusual cause of epileptic seizures in young children.

Pauwels S, Lemmens F, Eerdekens K, Penders J, Poesen K, Desmet K, Vermeersch P.

Eur J Pediatr. 2013 Nov;172(11):1547-50. doi: 10.1007/s00431-013-2080-x. Epub 2013 Jul 5. Review.

PMID:
23828132
39.

Inhibition of tumor angiogenesis and growth by a small-molecule multi-FGF receptor blocker with allosteric properties.

Bono F, De Smet F, Herbert C, De Bock K, Georgiadou M, Fons P, Tjwa M, Alcouffe C, Ny A, Bianciotto M, Jonckx B, Murakami M, Lanahan AA, Michielsen C, Sibrac D, Dol-Gleizes F, Mazzone M, Zacchigna S, Herault JP, Fischer C, Rigon P, Ruiz de Almodovar C, Claes F, Blanc I, Poesen K, Zhang J, Segura I, Gueguen G, Bordes MF, Lambrechts D, Broussy R, van de Wouwer M, Michaux C, Shimada T, Jean I, Blacher S, Noel A, Motte P, Rom E, Rakic JM, Katsuma S, Schaeffer P, Yayon A, Van Schepdael A, Schwalbe H, Gervasio FL, Carmeliet G, Rozensky J, Dewerchin M, Simons M, Christopoulos A, Herbert JM, Carmeliet P.

Cancer Cell. 2013 Apr 15;23(4):477-88. doi: 10.1016/j.ccr.2013.02.019.

40.

Therapeutic potential of VEGF and VEGF-derived peptide in peripheral neuropathies.

Verheyen A, Peeraer E, Lambrechts D, Poesen K, Carmeliet P, Shibuya M, Pintelon I, Timmermans JP, Nuydens R, Meert T.

Neuroscience. 2013 Aug 6;244:77-89. doi: 10.1016/j.neuroscience.2013.03.050. Epub 2013 Apr 11.

PMID:
23583762
41.

Performance of cassette-based blood gas analyzers to monitor blood glucose and lactate levels in a surgical intensive care setting.

Poesen K, De Prins M, Van den Berghe G, Van Eldere J, Vanstapel F.

Clin Chem Lab Med. 2013 Jul;51(7):1417-27. doi: 10.1515/cclm-2012-0848.

PMID:
23492571
42.

Interference of ethylene glycol with lactate measurement: a comparison study on new generation cassette-based blood gas analyzers.

Poesen K, Degandt S, Boes J, Vanstapel F, Desmet K, Vermeersch P.

Clin Chim Acta. 2012 Dec 24;414:18-9. doi: 10.1016/j.cca.2012.07.013. Epub 2012 Jul 20. No abstract available.

PMID:
22841681
43.

Systemic anti-vascular endothelial growth factor therapies induce a painful sensory neuropathy.

Verheyen A, Peeraer E, Nuydens R, Dhondt J, Poesen K, Pintelon I, Daniels A, Timmermans JP, Meert T, Carmeliet P, Lambrechts D.

Brain. 2012 Sep;135(Pt 9):2629-41. doi: 10.1093/brain/aws145. Epub 2012 Jun 25.

PMID:
22734125
44.

Relapsing Brevibacterium casei peritonitis: value of 16S rRNA gene sequencing in accurate species identification.

Poesen K, Meeus G, Boudewijns M, Colaert J, Doubel P.

Perit Dial Int. 2012 May-Jun;32(3):341-4. doi: 10.3747/pdi.2011.00179. No abstract available.

45.

Neuronal FLT1 receptor and its selective ligand VEGF-B protect against retrograde degeneration of sensory neurons.

Dhondt J, Peeraer E, Verheyen A, Nuydens R, Buysschaert I, Poesen K, Van Geyte K, Beerens M, Shibuya M, Haigh JJ, Meert T, Carmeliet P, Lambrechts D.

FASEB J. 2011 May;25(5):1461-73. doi: 10.1096/fj.10-170944. Epub 2011 Jan 19.

46.

Matrix-binding vascular endothelial growth factor (VEGF) isoforms guide granule cell migration in the cerebellum via VEGF receptor Flk1.

Ruiz de Almodovar C, Coulon C, Salin PA, Knevels E, Chounlamountri N, Poesen K, Hermans K, Lambrechts D, Van Geyte K, Dhondt J, Dresselaers T, Renaud J, Aragones J, Zacchigna S, Geudens I, Gall D, Stroobants S, Mutin M, Dassonville K, Storkebaum E, Jordan BF, Eriksson U, Moons L, D'Hooge R, Haigh JJ, Belin MF, Schiffmann S, Van Hecke P, Gallez B, Vinckier S, Chédotal A, Honnorat J, Thomasset N, Carmeliet P, Meissirel C.

J Neurosci. 2010 Nov 10;30(45):15052-66. doi: 10.1523/JNEUROSCI.0477-10.2010.

47.

Impaired autonomic regulation of resistance arteries in mice with low vascular endothelial growth factor or upon vascular endothelial growth factor trap delivery.

Storkebaum E, Ruiz de Almodovar C, Meens M, Zacchigna S, Mazzone M, Vanhoutte G, Vinckier S, Miskiewicz K, Poesen K, Lambrechts D, Janssen GM, Fazzi GE, Verstreken P, Haigh J, Schiffers PM, Rohrer H, Van der Linden A, De Mey JG, Carmeliet P.

Circulation. 2010 Jul 20;122(3):273-81. doi: 10.1161/CIRCULATIONAHA.109.929364. Epub 2010 Jul 6.

PMID:
20606119
48.

VEGF protects motor neurons against excitotoxicity by upregulation of GluR2.

Bogaert E, Van Damme P, Poesen K, Dhondt J, Hersmus N, Kiraly D, Scheveneels W, Robberecht W, Van Den Bosch L.

Neurobiol Aging. 2010 Dec;31(12):2185-91. doi: 10.1016/j.neurobiolaging.2008.12.007. Epub 2009 Jan 29.

PMID:
19185395
49.

Novel role for vascular endothelial growth factor (VEGF) receptor-1 and its ligand VEGF-B in motor neuron degeneration.

Poesen K, Lambrechts D, Van Damme P, Dhondt J, Bender F, Frank N, Bogaert E, Claes B, Heylen L, Verheyen A, Raes K, Tjwa M, Eriksson U, Shibuya M, Nuydens R, Van Den Bosch L, Meert T, D'Hooge R, Sendtner M, Robberecht W, Carmeliet P.

J Neurosci. 2008 Oct 15;28(42):10451-9. doi: 10.1523/JNEUROSCI.1092-08.2008.

50.

Meta-analysis of vascular endothelial growth factor variations in amyotrophic lateral sclerosis: increased susceptibility in male carriers of the -2578AA genotype.

Lambrechts D, Poesen K, Fernández-Santiago R, Al-Chalabi A, Del Bo R, Van Vught PW, Khan S, Marklund SL, Brockington A, van Marion I, Anneser J, Shaw C, Ludolph AC, Leigh NP, Comi GP, Gasser T, Shaw PJ, Morrison KE, Andersen PM, Van den Berg LH, Thijs V, Siddique T, Robberecht W, Carmeliet P.

J Med Genet. 2009 Dec;46(12):840-6. doi: 10.1136/jmg.2008.058222. Epub 2008 Apr 15.

PMID:
18413368

Supplemental Content

Loading ...
Support Center